<DOC>
	<DOCNO>NCT03042481</DOCNO>
	<brief_summary>Pegylated-interferon ( Peg-IFN ) α-2a , entecavir ( ETV ) tenofovir disoproxil fumarate ( TDF ) current recommend first-line antiviral therapy chronic hepatitis B ( CHB ) . Compared Peg-IFN therapy , nucleot ( ) ide analogue ( NUC ) therapy advantage potent antiviral effect , good tolerance without side effect . The long-term safety efficacy ETV TDF therapy also identify . However , poor durability effectiveness stop NUC therapy encounter majority patient . Previous study identify high HBV relapse rate 50 % HBeAg- positive CHB patient treat lamivudine . A recent study investigate post-treatment durability ETV show high 45.3 % HBeAg-negative CHB patient happen clinical relapse within 1-year stop ETV therapy . TDF another recommend first line NUC high potency high genetic barrier . Although efficacy long-term TDF therapy identify , lack data regard off-therapy response CHB patient TDF therapy currently . Only small scale patient treat TDF include recent study investigate off-therapy relapse non-cirrhotic HBeAg-negative CHB patient great 4 year NUC therapy . In addition , factor associate off-therapy response also still uncertain . The investigator plan enrol 400 CHB patient receive oral antiviral therapy ETV TDF achieve Asia Pacific association study liver ( APASL ) criteria stop NUC therapy . The aim study investigate rate HBV relapse include virological clinical relapse patient ETV TDF therapy , identify predictive factor relapse .</brief_summary>
	<brief_title>Off-therapy Response After Stopping Entecavir Tenofovir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female patient &gt; 20 year age 2 . Positive HBsAg 6 month prior ETV TDF therapy . 3 . HBV DNA ≥20,000 IU/mL alanine aminotransferase ( ALT ) level ≥ 2 fold upper limit normal ( ULN ) HBeAgpositive patient , HBV DNA ≥2000 IU/mL ALT level ≥ 2 fold ULN HBeAgnegative patient prior ETV TDF therapy . 4 . Achieve APASL criterion stop NUC therapy include HBeAg seroconversion ( negative HBeAg positive HBeAb ) HBV DNA loss measure two consecutive occasion least 6 month apart HBeAg positive patient ; 2 year therapy undetectable HBV DNA document three separate occasion 6 month apart HBeAg negative patient . 1 . Hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) coinfection . 2 . History evidence medical condition associate chronic liver disease CHB ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) 3 . Evidence drug abuse ( include excessive alcohol consumption ) . 4 . Prophylactic use ETV TDF therapy . ( cancer chemotherapy posttransplant immunosuppressive therapy prophylaxis ) 5 . Patients clinical evidence liver cirrhosis . 6 . Inability unwillingness provide inform consent abide requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>entecavir</keyword>
	<keyword>tenofovir</keyword>
	<keyword>off-therapy</keyword>
	<keyword>relapse</keyword>
</DOC>